Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
In this educational workshop, Parexel regulatory experts, all former regulators, provide a comprehensive view of anti-drug conjugates (ADCs) for the treatment of cancer - from non-clinical, CMC, and clinical perspectives. In this 90-minute educational session, we explore how ADCs are developed and characterized in the non-clinical stage, the critical considerations, and challenges in manufacturing processes (CMC), and the exciting clinical developments shaping the landscape of cancer therapy. Join us as we delve into the multidimensional aspects of ADCs and their potential to revolutionize cancer treatment.
Related Insights
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Related Insights
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023